Vinorelbine

CHEMBL553025 Phase 4 Onaylandı Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
778.9 g/mol
LogP
3.6
Phase
4

This semi-synthetic vinca alkaloid chemotherapy is used to treat non-small cell lung cancer and breast cancer, either alone or in combination with other chemotherapy agents. Like other vinca alkaloids, it works by blocking cell division by preventing the formation of the mitotic spindle in cancer cells. It can be given intravenously or as an oral capsule, and peripheral neuropathy and bone marrow suppression are the main side effects.

Moleküler Ağırlık

778,9000 g/mol

LogP

3,60

TPSA

134,00 Ų

Lipinski RO5

Başarısız

Terapötik Alanlar

Pharmacokinetics (PK)

Pharmacodynamics (PD)

2D Yapı

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

CCC1=C[C@@H]2CN(C1)Cc1c([nH]c3ccccc13)[C@@](C(=O)OC)(c1cc3c(cc1OC)N(C)[C@H]1[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]4(CC)C=CCN5CC[C@]31[C@@H]54)C2

InChI

InChI=1S/C45H54N4O8/c1-8-27-19-28-22-44(40(51)55-6,36-30(25-48(23-27)24-28)29-13-10-11-14-33(29)46-36)32-20-31-34(21-35(32)54-5)47(4)38-43(31)16-18-49-17-12-15-42(9-2,37(43)49)39(57-26(3)50)45(38,53)41(52)56-7/h10-15,19-21,28,37-39,46,53H,8-9,16-18,22-25H2,1-7H3/t28-,37-,38+,39+,42+,43+,44-,45-/m0/s1

Molecular Formula

C45H54N4O8

HBD / HBA

2 / 11

Döndürülebilir Bağlar

10

Ağır Atomlar

57

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Sıkça Sorulan Sorular

This semi-synthetic vinca alkaloid chemotherapy is used to treat non-small cell lung cancer and breast cancer, either alone or in combination with other chemotherapy agents. Like other vinca alkaloids, it works by blocking cell division by preventing the formation of the mitotic spindle in cancer cells. It can be given intravenously or as an oral capsule, and peripheral neuropathy and bone marrow suppression are the main side effects.

Yes, Vinorelbine is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL553025. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 5311497. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

Tıbbi Sorumluluk Reddi

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.